Posted by Michael Wonder on 19 Feb 2020
FDA touts generic drug research in 2019
19 February 2020 - The US FDA on Tuesday released a report detailing the scientific research carried out and funded by the agency in FY2019 to support the development of generic drugs under the Generic Drug User Fee Amendments.
The 83-page report provides an overview of the research activities related to 13 research areas that fit within the four scientific priorities FDA set for FY2019, which include: complex active ingredients, formulations or dosage forms; complex routes of delivery; complex drug-device combination products; and tools and methodologies for bioequivalence and substitutability evaluation.
